Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

Leukemia

Volumn 16, Issue 7, 2002, Pages 1331-1343

  Almenara, J ^a   Rosato, R ^a   Grant, S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cytochrome c; Flavopiridol; Histone deacetylase inhibitor; Leukemia; SAHA

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ACETYLCYSTEINE; CASPASE 3; CASPASE 8; CD11B ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; ENZYME PRECURSOR; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE C INHIBITOR; PROTEIN P21; RETINOBLASTOMA PROTEIN; SCAVENGER; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME RELEASE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0036050151     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402535     Document Type: Article

References (50)

1. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
2. Sodium butyrate inhibits histone deacetylation in cultured cells
3. Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate
4. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report
5. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells
6. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
7. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation
8. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
9. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53
10. Inhibitors of histone deacetylase are potentially effective anticancer agents
11. Mechanisms of action of flavopiridol
12. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
13. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
14. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies
15. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
16. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials
17. Determination of flavopiridol (L868175; NSC 649890) in human plasma by reversed phase liquid chromatography with electrochemical detection
18. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
19. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells
20. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
21. WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis
22. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade
23. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60)
24. Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01)
25. Conversion of Bcl-2 to a Bax-like death effector by caspases
26. Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis
27. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in leukemia cells (U937)
28. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
29. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis
30. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release
31. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
32. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway
33. The control of phospholipid methylation by phorbol diesters in differentiating human myeloid HL-60 leukemia cells
34. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
35. Progression of the myeloid differentiation program is dominant to transforming growth factor-beta 1-induced apoptosis in M1 myeloid leukemic cells
36. Activation of protein kinase C relays distinct signaling pathways in the same cell type: Differentiation and caspase-mediated apoptosis
37. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells
38. p21Cip1/WAF1 is important for differentiation and survival of U937 cells
39. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation
40. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation
41. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
42. Flavopiridol binds to duplex DNA
43. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
44. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway
45. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
46. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death
47. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
48. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
49. Mitochondrion as a novel target of anticancer chemotherapy
50. CIP1 expression and maturation while enhancing apoptosis in human myeloid leukemia cells